Vaccines for Yersinia pestis


  1. Kournikakis, B.
Corporate Authors
Defence Research Establishment Suffield, Ralston ALTA (CAN);Saskatchewan Univ, Saskatoon SasK (CAN) Veterinary Infectious Disease Organization
The objective of this research contract was to construct prototype vectored vaccines producing Yersinia pestis antigens and to test their ability to protect mice against experimental challenge. In addition, the work described in Appendices A and B to Annex A dealt with the potential of intranasally-delivered conventiona Y. pestis antigens formulated in liposomes to protect against pneumonic plague. The genes coding for the pH6 and V antigens were obtained from researchers in the United States. They were expressed at high levels in Escherichia coli in order to produce subunit antigens needed for immunological assays as well as to raise specific polyclonal antiserum in rabbits. The gene coding for the V antigen genes were inserted into the E3 region of human adenovirus while both the pH6 operon as well as the V antigen was inserted into live-attenuated E. coli vaccine strains. These prototype vaccine strains were fully characterized and delivered to the Defence Research Establishment Suffield for vaccine testing. Immunization of mice at mucosal sites did not result in the induction of protective immunity. A second set of experiments described in Annex A as well as Appendices A and B dealt with the feasibility of reformulating the existing whole cell plague vaccine into liposomes for intranasal immunization. TRUNCATED
Yersinia pestis;Protective Antigen;Intranasal delivery;Antibody response
Report Number
DRES-CR-2001-038 — Contractor Report (Final Report)
Date of publication
01 Jan 2001
Number of Pages
Hardcopy;Document Image stored on Optical Disk

Permanent link

Document 1 of 1

Date modified: